July 18, 2004
July 18, 2004
Alzheimer’s expert and research pioneer Barry Reisberg, M.D., was today awarded a lifetime achievement award at the Ninth International Conference on Alzheimer’s Disease and Related Disorders in Philadelphia. The award recognizes scientists who have made extraordinary contributions in exploring the causes of Alzheimer’s, how it progresses, and ways it can be monitored and treated, plus possible strategies for slowing its progression and delaying or preventing its onset.
We are delighted that Dr. Reisberg was recognized for his achievements in working towards a cure for Alzheimer’s disease. Dr. Reisberg has long been a valued member of the Fisher Center and www.ALZinfo.org Advisory Board and a leader in the field of Alzheimer’s disease research. Through his body of scientific work and throughout his distinguished career, he has made multiple valuable contributions to the Alzheimer’s disease field.
Dr. Reisberg is a psychiatrist and leading expert in Alzheimer’s disease. For the past twenty five years, Dr. Reisberg has served as the Clinical Director of New York University’s Aging and Dementia Research Center and is the director of the Fisher Alzheimer’s Disease Education and Resources Program at New York University. As the principal investigator of studies conducted by the National Institutes of Health, Dr. Reisberg’s work has been pivotal in the development of two of the three current pharmaceutical treatment modalities for Alzheimer’s. His rating scales and descriptions of the nature and course of Alzheimer’s are widely used throughout the world.
Recently, Dr. Reisberg directed national studies that have uncovered a new chemical messenger approach to the treatment of Alzheimer’s using, in large part, the scientific assessment measures that he has pioneered. His body of research has included extensive studies on Namenda (also called memantine), the first drug to be approved for those with the more advanced stages of Alzheimer’s disease. [See the article, “Breakthrough Drug Offers New Hope for Advanced Alzheimer’s.”]
Dr. Reisberg’s research has also recently uncovered a new fundamental biologic process, which he has termed “retrogenesis”, which occurs in Alzheimer’s and other dementing disorders. The retrogenesis process explains the nature of the clinical symptoms of Alzheimer’s disease and associated management needs and provides a new direction for fundamental treatment investigation. Dr. Reisberg has contributed to more than 200 scientific publications. He is the author of A Guide to Alzheimer’s Disease and editor of a reference text, Alzheimer’s Disease, both published by Macmillan.
In addition to serving on the advisory board of the Fisher Center for Alzheimer’s Research Foundation, Dr. Reisberg has served on the Medical and Scientific Advisory Board of the Alzheimer’s Association (USA) and serves on the Medical and Scientific Advisory Board of Alzheimer’s Disease International (ADI). He has served as President of the International Psychogeriatric Association. In this capacity, he has presided over meetings in Beijing, China; Berlin, Germany; Istanbul, Turkey; and the largest congress ever held in his field of geriatric psychiatry, in Vancouver, Canada.
In addition to Dr. Reisberg, other recipients of the Lifetime Achievement Award were:
– John C. Morris, M.D., the Friedman Distinguished Professor of Neurology, at Washington University in St Louis, where he directs the Alzheimer Disease Research Center and the Center for Aging.
– Donald. L. Price, M.D., Professor of Pathology, Neurology, and Neuroscience at The Johns Hopkins University School of Medicine, a neurologist-neuropathologist-neurobiologist.
– Joseph Rogers, Ph.D., who founded the Sun Health Research Institute in Sun City, Arizona in 1986. Sun Health Research Institute has 31 M.D. or Ph.D. faculty, and is the recipient of an NIH-supported Alzheimer’s Disease Core Center in a consortium with other Arizona institutions.
By www.ALZinfo.org, The Alzheimer’s Information Site.